IZO:CC - Izotropic Engages Market Awareness Consultant
(TheNewswire)
VANCOUVER, BC – TheNewswire - JUNE 27,2023 – Izotropic Corporation (“ Izotropic ” orthe “ Company ”) (CSE: IZO ) (OTC: IZOZF )(FSE: 1R3 ), a medical device company commercializing IzoView, a360-degree computed tomography (CT) imaging system designed for breastimaging announced that it has engaged Douglas McKay andAssociates (“ DMA ”) to assist theCompany with its communications and financing initiatives.
Subject to necessary approvals from the CanadianSecurities Exchange, DMA has been engaged underthe following agreement terms:
Agreement Length:
-
6 (six) months, with an option to extend.
Re mun eration:
-
Monthly fee of $7,000.00 CAD per month that will be deferred until theCompany completes its next financing (currently undertaking); and
-
400,000 stock options at an exercise price of $0.275 for a 2 (two)year term. The stock options will vest according to the followingschedule: 50% of the stock options will vest on September 27th, 2023,and 50% of the stock options on December 27th, 2023; and
-
300,000 restricted share units. The restricted share units will vestaccording to the following schedule: 100,000 shares on August 27th,2023, 100,000 shares on October 27th, 2023, and 100,000 shares onDecember 27th, 2023.
Izotropic had previously engaged DMA in 2020 as part ofits awareness building initiatives. DMA was effective at attractingmany new shareholders and assisted the Companyby introducing several medical professionals and other individuals whoparticipated into 2 (two) separate financings completed in 2020. TheCompany looks forward to working with DMA again as it moves forwardson its recently announced modified market approval pathway and strategy for FDA market clearance in the USA.
ON BEHALF OF THE BOARD
Mr. Robert Thast, CEO
Cell: 604-220-5031
Contact:
Email: info@izocorp.com
Toll Free: 1-833-IZOCORP ext.1
About Izotropic Corporation
More information about Izotropic Corporation can befound on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
Forward-Looking Statements
This document may contain statements that are"Forward-Looking Statements," which are based upon thecurrent estimates, assumptions, projections, and expectations of theCompany's management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify suchinformation and statements by using words such as"anticipate," "believe,""envision," "estimate," "expect,""intend," "may," "plan,""predict," "project," "target,""potential," "will," "would,""could," "should," "continue,""contemplate" and other similar expressions and derivationsthereof in connection with any discussion of future events, trends orprospects or future operating or financial performance, although notall forward-looking statements contain these identifying words.
These statements are not guarantees of performance andinvolve risks, including those related to capital requirements anduncertainties that are difficult to control or predict, and as such,they may cause future results of the Company's activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the Company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information orthe occurrence of future events or circumstances unless otherwiserequired to do so by law. Neither the Company nor its shareholders,officers, and consultants shall be liable for any action and theresults of any action taken by any person based on the informationcontained herein, including, without limitation, the purchase or saleof Company securities. Nothing in this document should be deemed to bemedical or other advice of any kind. All images are for illustrativepurposes only. IzoView is not yet approved for sale.
Copyright (c) 2023 TheNewswire - All rights reserved.